Melillo RM - Search Results

1

Mast cells have a protumorigenic role in human thyroid cancer.

Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A, Santoro M, Marone G. Melillo RM, et al. Oncogene. 2010 Nov 25;29(47):6203-15. doi: 10.1038/onc.2010.348. Epub 2010 Aug 23. Oncogene. 2010. PMID: 20729915

2

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al. Santoro M, et al. J Clin Invest. 1992 May;89(5):1517-22. doi: 10.1172/JCI115743. J Clin Invest. 1992. PMID: 1569189 Free PMC article.

3

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. Grieco M, et al. Among authors: melillo rm. Cell. 1990 Feb 23;60(4):557-63. doi: 10.1016/0092-8674(90)90659-3. Cell. 1990. PMID: 2406025

4

Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation.

Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G. Santoro M, et al. Among authors: melillo rm. Eur J Endocrinol. 1995 Nov;133(5):513-22. doi: 10.1530/eje.0.1330513. Eur J Endocrinol. 1995. PMID: 7581978 Review.

5

Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo.

Grieco M, Cerrato A, Santoro M, Fusco A, Melillo RM, Vecchio G. Grieco M, et al. Among authors: melillo rm. Oncogene. 1994 Sep;9(9):2531-5. Oncogene. 1994. PMID: 8058316

6

The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line.

Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A. Santoro M, et al. Among authors: melillo rm. Cell Growth Differ. 1993 Feb;4(2):77-84. Cell Growth Differ. 1993. PMID: 8494786

7

Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M. Carlomagno F, et al. Among authors: melillo rm. EMBO J. 1996 Jun 3;15(11):2717-25. EMBO J. 1996. PMID: 8654369 Free PMC article.

8

The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.

Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M. Carlomagno F, et al. Among authors: melillo rm. Cancer Res. 1997 Feb 1;57(3):391-5. Cancer Res. 1997. PMID: 9012462

9

Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.

Cirafici AM, Salvatore G, De Vita G, Carlomagno F, Dathan NA, Visconti R, Melillo RM, Fusco A, Santoro M. Cirafici AM, et al. Among authors: melillo rm. Endocrinology. 1997 Apr;138(4):1450-5. doi: 10.1210/endo.138.4.5073. Endocrinology. 1997. PMID: 9075701

10

Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors.

De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A, Santoro M. De Vita G, et al. Among authors: melillo rm. Cell Growth Differ. 1998 Jan;9(1):97-103. Cell Growth Differ. 1998. PMID: 9438393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters